For Investors

Close

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

EUROPE—
HEADQUARTERS

FRANCE

THE NETHERLANDS

SWITZERLAND

AUSTRIA

GERMANY

NORWAY

UNITED KINGDOM

DENMARK

ITALY

SPAIN

Home > Investor Relations

Investor Relations

Overview

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Events & Presentations

Upcoming

More events are coming soon.

View All Events

Prior

Monday January 13, 2020 at 9:00 AM PST
J. P. Morgan 38th Annual Healthcare Conference Q/A Session

Monday January 13, 2020 at 8:30 AM PST
J. P. Morgan 38th Annual Healthcare Conference Presentation

Monday January 13, 2020 at 7:00 AM PST
Tafasitamab Collaboration Webcast

View All Events

Press Releases

January 23, 2020

Incyte to Report Fourth Quarter and Year-End Financial Results


January 13, 2020

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab


January 7, 2020

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma


View All Releases

Investor Contacts

Michael Booth D.Phil
Division VP, Investor Relations & Corporate Responsibility
Phone: 302.498.5914
mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility
Phone: 302.498.6141
layala@incyte.com

Christine Chiou
Senior Director, Investor Relations
Phone: 302.274.4773
cchiou@incyte.com

Copyright West LLC. Minimum 15 minutes delayed.

Annual Reports

Quarterly Reports

RSS Feeds


All Press Releases

All Events

All SEC Filings